Acumen starts Phase 1 for monoclonal antibody for Alzheimer's

 Acumen Pharmaceuticals Inc., (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease. Acumen is on track to report topline results, including safety and proof-of-mechanism data, in the third quarter of 2023, which is earlier than previously expected.

https://www.biospace.com/article/acumen-pharmaceuticals-completes-enrollment-in-phase-1-trial-of-acu193-first-monoclonal-antibody-developed-to-selectively-target-toxic-a%ce%b2-oligomers-in-patients-with-early-alzheimer-s-disease/